FDA Abandons Two-Trial Standard: Implications for Drug Development

The FDA announced on February 18, 2026, that it will no longer require two pivotal clinical trials for new drug approvals, establishing a single-trial approach as the default standard. In a New England Journal of Medicine perspective, FDA leaders argued that the “two-trial dogma”, unchallenged since the 1960s, is obsolete given advances in biology, statistical inference, and confirmatory evidence from Phase 2 trials and mechanistic studies. This policy formalizes existing FDA flexibility, where approximately 60% of first-of-a-kind drugs approved in recent years relied on single pivotal trials, particularly in oncology and rare diseases.

Importantly, oncology has long benefited from exceptions to the two-trial requirement. The FDA’s accelerated approval pathway and oncology-specific guidance have routinely accepted single Phase 3 trials supported by surrogate endpoints or Phase 2 data, enabling faster access to therapies for serious conditions.

Clinical trial designs will adapt accordingly. Traditional sequential Phase 1-2-single Phase 3 approaches become more viable, while seamless Phase 2/3 adaptive trialsal gain further traction. These integrated designs use interim analyses to transition from effective dose-finding  to confirmatory efficacy within one continuous study, optimizing efficiency without compromising statistical rigor.

Artificial intelligence further accelerates this transformation, shortening preclinical development by 30-50% through rapid target identification, virtual screening, and predictive toxicology. Insilico Medicine’s rentosertib program, for example, completed AI-driven preclinical work and IND-enabling studies in under 18 months versus the conventional 3-5 years. Combined with single-trial approvals, such technologies could compress total timelines from 10-15 years to 5-8 years.

This shift promises broader therapeutic innovation, particularly for unmet needs in fields like prostate cancer, while building on oncology’s established precedent for flexible, evidence-based approvals.

Source.